Bortemap 2mg Injection

Bortemap 2 mg injection is a chemotherapy medication belonging to the class of proteasome inhibitors. The active ingredient is Bortezomib. It is indicated for treatment of multiple myeloma and mantle cell lymphoma. Multiple myeloma is a malignancy of plasma cells that originates in the bone marrow. Mantle cell lymphoma is a less common lymph node cancer. This medication is used concurrently with other chemotherapy medicines including pegylated liposomal doxorubicin, rituximab, cyclophosphamide, doxorubicin, dexamethasone, prednisolone, or thalidomide for patients with previously untreated disease who are ineligible for blood stem cell transplant. Common side effects associated with Bortemap 2 mg injection include pneumonia, loss of appetite, sensitivity, tingling and burning sensation of the skin, nausea, vomiting, diarrhoea, mouth ulcers, constipation, muscle and bone pain, hair loss, fever, infections, itching, redness, dehydration, and gastrointestinal problems. Inform your physician if these side effects occur or persist. Inform your doctor if you are allergic to Bortemap 2 mg injection and its ingredients. Do not use this medication if you have severe lung or cardiac problems. Before starting treatment with this medication, inform your physician if you have neuropathy (nerve malfunction), cardiac disorders, severe lung problems, pulmonary disorders, posterior reversible encephalopathy syndrome disorders, gastrointestinal disorders, thrombocytopenia (low platelet count), neutropenia (low white blood cell count), tumour lysis syndrome (metabolic abnormalities that can occur as a complication during cancer treatment), or hepatic disorders. Inform your doctor if you have diabetes, as Bortemap 2 mg injection can affect blood glucose levels.

Treatment of multiple myeloma and mantle cell lymphoma.

Bortemap 2 mg injection works by exerting a toxic effect on cancer cells. It inhibits the 26S proteasome and blocks a major cell signaling pathway. This inhibition of the signaling pathway makes the cancer cells sensitive to chemotherapy. This medicine also enhances the build-up of a protein and minimizes cancer cell growth and multiplication.

Bortemap 2 mg injection is administered intravenously in your vein or subcutaneously under the skin. This injection should be given by a qualified healthcare professional experienced in the use of cytotoxic medications.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious: Muscle cramps Confusion, visual disturbances, seizures, and headache Breathlessness Swelling of feet Changes in heartbeat High blood pressure Fainting and tiredness Cough and chest tightness Common: Pneumonia Loss of appetite Sensitivity, tingling and burning sensation of the skin. Nausea, vomiting, and diarrhea Mouth ulcers Constipation Muscle and bone pain Hair loss Fever Reduction in blood cell count Reduced kidney function Shivering Infections Itching and redness Dehydration Stomach problems Difficulty sleeping, anxiety, mood swings, depressed mood.

It is advised that both men and women must use an effective contraception method during treatment and three months afterward. Treatment with Bortemap 2 mg injection can commonly cause a decrease in the number of red and white blood cells and platelets in your blood. Therefore, you will have to take regular blood tests before and during your treatment with bortezomib to check your blood cell counts regularly. Pregnant women should not handle Bortemap 2 mg injection as it contains cytotoxic agents. Using gloves and protective clothing is recommended to prevent skin contact.